FOOD EFFECT STUDY OF THE INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Falchook, G. S. [1 ]
Zhou, X. [2 ]
Rosen, L. S. [3 ]
Venkatakrishnan, K. [2 ]
Kurzrock, R. [1 ]
Mahalingam, D. [4 ]
Goldman, J. [5 ]
Jung, J. [6 ]
Milch, C. [2 ]
Sarantopoulos, J. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Millennium Pharmaceut Inc, Clin Pharmacol, Cambridge, MA USA
[3] Premiere Oncol, Oncol, Santa Monica, CA USA
[4] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Inst Drug Dev, San Antonio, TX 78229 USA
[5] UCLA Med Ctr, David Geffen Sch Med, Div Hematol Oncol, Santa Monica, CA USA
[6] Millennium Pharmaceut Inc, Biostat, Cambridge, MA USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：168 / 168
页数：1
相关论文
共 50 条
  • [41] Phase 2 Trial of Alisertib (MLN8237), An Investigational, Potent Inhibitor of Aurora A Kinase (AAK), in Patients (pts) with Aggressive B- and T-Cell Non-Hodgkin Lymphoma (NHL)
    Friedberg, Jonathan
    Mahadevan, Daruka
    Jung, JungAh
    Persky, Daniel O.
    Lossos, Izidore S.
    Danaee, Hadi
    Zhou, Xiaofei
    Leonard, E. Jane
    Bernstein, Steven H.
    BLOOD, 2011, 118 (21) : 46 - 46
  • [42] PHASE 1 STUDY OF MLN8237 (ALISERTIB) IN ADULT EAST ASIAN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS OR LYMPHOMAS
    Kim, W. S.
    Venkatakrishnan, K.
    Kim, T. M.
    Lin, C. -C.
    Thye, L. S.
    Chng, W. J.
    Ma, B.
    Chen, M. -H.
    Liu, H.
    Benaim, E.
    ANNALS OF ONCOLOGY, 2013, 24
  • [43] Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchlano, Alfonso
    Crippa, Flavlo
    Togllardi, Elena
    Daldone, Maria Grazla
    Gianni, Alessandro M.
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] INVESTIGATIONAL AURORA A KINASE (AAK) INHIBITOR MLN8237 (ALISERTIB) SUPPRESSES NEUROSPHERE PROLIFERATION OF PEDIATRIC GLIOBLASTOMA AND PROLONGS ANIMAL SURVIVAL IN PATIENT TUMOR-DERIVED ORTHOTOPIC XENOGRAFT MOUSE MODEL
    Kogiso, Mari
    Zhang, Linna
    Qi, Lin
    Lindsay, Holly
    Lin, Frank
    Berg, Stacey
    Li, Xiao-Nan
    Muscal, Jodi
    NEURO-ONCOLOGY, 2014, 16 : 52 - 52
  • [45] Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
    Dees, E. Claire
    Cohen, Roger B.
    von Mehren, Margaret
    Stinchcombe, Thomas E.
    Liu, Hua
    Venkatakrishnan, Karthik
    Manfredi, Mark
    Fingert, Howard
    Burris, Howard A., III
    Infante, Jeffrey R.
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4775 - 4784
  • [46] Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
    Matulonis, Ursula A.
    Sharma, Sudarshan
    Ghamande, Sharad
    Gordon, Michael S.
    Del Prete, Salvatore A.
    Ray-Coquard, Isabelle
    Kutarska, Elzbieta
    Liu, Hua
    Fingert, Howard
    Zhou, Xiaofei
    Danaee, Hadi
    Schilder, Russell J.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 63 - 69
  • [47] Aurora kinase a inhibitor MLN8237 suppresses pancreatic cancer growth
    Zhang, Yuebo
    Ma, Yong
    Wang, Ying
    Mukhopadhyay, Debabrata
    Bi, Yan
    Ji, Baoan
    PANCREATOLOGY, 2022, 22 (05) : 619 - 625
  • [48] Mass balance, routes of excretion and pharmacokinetics of investigational oral [14C] alisertib (MLN8237) in patients with advanced solid tumors or lymphoma.
    Zhou, Xiaofei
    Pusalkar, Sandeepraj
    Ghowdhury, Swapan
    Searle, Shawn
    Li, Yuexian
    Mertz, Jaime
    Zhang, Bin
    Ben, Yong
    Venkatakrishnan, Karthik
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [49] Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcomaaEuro
    Dickson, M. A.
    Mahoney, M. R.
    Tap, W. D.
    D'Angelo, S. P.
    Keohan, M. L.
    Van Tine, B. A.
    Agulnik, M.
    Horvath, L. E.
    Nair, J. S.
    Schwartz, G. K.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1855 - 1860
  • [50] Phase I dose-escalation study of the investigational Aurora A kinase (AAK) inhibitor MLN8237 as an enteric-coated tablet (ECT) formulation in patients with nonhematologic malignancies.
    Sharma, S.
    Kurzrock, R.
    Gouw, L.
    Hong, D. S.
    Jones, K.
    Zhou, X.
    Shi, H.
    Fingert, H.
    Falchook, G. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345